IMRT同步化疗后度伐利尤单抗治疗III期NSCLC的多中心回顾研究
该多中心回顾性研究纳入7家日本机构的107例III期NSCLC患者,接受IMRT同步化疗后81%使用度伐利尤单抗。肺炎总发生率89%,≥2级肺炎与年龄≥70岁、男性及肺V5≥58.9%显著相关;建议V5<60%以减少症状性肺炎。
要点
- IMRT同步化疗后度伐利尤单抗总体有效且可耐受。
- 年龄≥70岁、男性、肺V5≥58.9%与≥2级肺炎显著相关。
- 建议肺V5<60%以降低症状性肺炎风险。
核心结论
- IMRT同步化疗后度伐利尤单抗治疗III期NSCLC总体有效且可耐受,建议V5<60%以避免症状性肺炎。
研究设计与样本
- 多中心回顾性研究,纳入7家日本机构接受IMRT同步化疗的NSCLC患者107例,中位年龄70岁,女性占29%。
主要发现
- 中位随访14.3个月,肺炎发生95例(89%),其中1级53%、2级28%、3级6.5%、4级0.9%。
- 87例(81%)接受度伐利尤单抗,其中16例(18.4%)因肺炎停药。
- 多因素分析显示年龄≥70岁、男性、V5≥58.9%与≥2级肺炎显著相关(P分别为0.0065、0.036、0.0013)。
- 接受度伐利尤单抗患者的中位PFS未达到(95%CI 14.2个月至未达到)。
- 中位肺V5为49.2%,中位肺V20为19.5%。
关键数值与推荐
- 肺V5≥58.9%与≥2级肺炎显著相关(P=0.0013),建议V5<60%。
- 年龄≥70岁与≥2级肺炎显著相关(P=0.0065)。
- 男性与≥2级肺炎显著相关(P=0.036)。
临床怎么用
- III期NSCLC接受IMRT同步化疗后行度伐利尤单抗治疗时,应关注肺V5并尽量控制在60%以下。
- 对年龄≥70岁男性患者应加强肺炎监测与随访。
局限性
- 回顾性研究设计,样本量107例,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) is increasingly applied in concurrent chemoradiotherapy (CCRT) for locally-advanced non-small cell lung cancer (NSCLC), with improvement of target coverage and better sparing of normal tissue. IMRT tends to have a larger low-dose irradiation volume than 3D conformal radiotherapy, but the incidence of and risk factors for pneumonitis remain unclear, especially following the approval of durvalumab. MATERIALS AND METHODS: We retrospectively reviewed the records of NSCLC patients treated by CCRT using IMRT at seven Japanese institutions. Primary outcomes were incidence of symptomatic pneumonitis and progression-free survival (PFS). Multivariate logistic regression analysis was used to identify risk factors for ≥grade 2 pneumonitis. RESULTS: Median follow-up from the start of CCRT was 14.3 months (n = 107 patients; median age 70 years, 29% female). Median lung V5 and V20 was 49.2% and 19.5%, respectively. Durvalumab was administered to 87 patients (81%). Pneumonitis developed in 95 (89%) patients of which 53% had grade 1, 28% grade 2, 6.5% grade 3, and 0.9% grade 4. Durvalumab had been discontinued in 16 patients (18.4%) due to pneumonitis. By multivariate analysis, age ≥70 years, male sex, and V5 ≥58.9% were identified as significantly associated with ≥grade 2 pneumonitis (p = 0.0065, 0.036 and 0.0013 respectively). The median PFS from the start of CCRT was not reached (95% CI, 14.2 months to not reached) in patients receiving durvalumab. CONCLUSION: CCRT using IMRT followed by durvalumab was generally effective and tolerable; V5 <60% would be recommended to avoid symptomatic pneumonitis.
引用
- Tsukita Y, Yamamoto T, Mayahara H, et al. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. Radiother Oncol. 2021. PMID: 34023330. doi:10.1016/j.radonc.2021.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。